These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 12124955)

  • 41. [Plaque inhibition with the GPIIb/IIIa antagonist Tirofiban].
    Z Kardiol; 1999 Apr; 88(4 Suppl):1-4. PubMed ID: 10355076
    [No Abstract]   [Full Text] [Related]  

  • 42. Safety and efficacy of tirofiban in stent-assisted coil embolization of intracranial aneurysms.
    Chalouhi N; Jabbour P; Kung D; Hasan D
    Neurosurgery; 2012 Sep; 71(3):710-4; discussion 714. PubMed ID: 22668886
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tirofiban: a critical reappraisal of the clinical use, recent developments and future perspectives.
    Valgimigli M; Campo G; Percoco G; Pellegrino L; Guardigli G; Ferrari R
    Future Cardiol; 2006 Jan; 2(1):17-27. PubMed ID: 19804127
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Platelet function after a high dose bolus of tirofiban immediately after coronary angioplasty].
    Barbou F; Frère C; Hovasse T; Cuisset T; Said LN; Quilici J; Alessi MC; Bonnet JL
    Arch Mal Coeur Vaiss; 2006 Oct; 99(10):894-9. PubMed ID: 17100140
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Restoration of normal coronary flow with tirofiban by intracoronary administration for no-reflow phenomenon after stent deployment.
    Yang TY; Chang ST; Chung CM; Cheng NJ
    Int Heart J; 2005 Jan; 46(1):139-45. PubMed ID: 15858946
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons.
    Hiramatsu Y; Gikakis N; Anderson HL; Gorman JH; Marcinkiewicz C; Gould RJ; Niewiarowski S; Edmunds LH
    J Thorac Cardiovasc Surg; 1997 Jan; 113(1):182-93. PubMed ID: 9011688
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Platelet Inhibition With IV Glycoprotein IIb/IIIa Inhibitor to Prevent Thrombosis in Pediatric Patients Undergoing Aortopulmonary Shunting.
    Emani S; Pereira LM; Piekarski BL; Diallo F; Chu E; Wesley MC; Thiagarajan R; Emani SM
    Pediatr Crit Care Med; 2020 Jun; 21(6):e354-e361. PubMed ID: 32168298
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Acute profound thrombocytopenia associated with tirofiban: clinical approach to diagnosis and therapeutic management].
    Agnelli D; Ottani F
    G Ital Cardiol (Rome); 2008 Feb; 9(2):137-43. PubMed ID: 18383777
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety of tirofiban therapy in korean patients with acute coronary syndrome.
    Jeong JH; Chun KJ; Park YH; Kim JH; Hong TJ; Shin YW
    Circ J; 2005 Jun; 69(6):650-3. PubMed ID: 15914940
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens.
    Heramvand N; Masyuk M; Muessig JM; Nia AM; Karathanos A; Polzin A; Valgimigli M; Gurbel PA; Tantry US; Kelm M; Jung C
    J Thromb Thrombolysis; 2022 Aug; 54(2):301-308. PubMed ID: 35482154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban.
    Schneider DJ; Herrmann HC; Lakkis N; Aguirre F; Lo MW; Yin KC; Aggarwal A; Kabbani SS; DiBattiste PM
    Am J Cardiol; 2003 Feb; 91(3):334-6. PubMed ID: 12565092
    [No Abstract]   [Full Text] [Related]  

  • 52. Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes.
    Brener SJ; Murphy SA; Gibson CM; DiBattiste PM; Demopoulos LA; Cannon CP;
    Am J Cardiol; 2002 Sep; 90(6):631-3. PubMed ID: 12231091
    [No Abstract]   [Full Text] [Related]  

  • 53. An in-vitro model to study device-induced thrombosis and embolism: evaluation of the efficacy of tirofiban, aspirin, and dipyridamole.
    Sukavaneshvar S; Solen KA; Mohammad SF
    Thromb Haemost; 2000 Feb; 83(2):322-6. PubMed ID: 10739393
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery.
    Genoni M; Zeller D; Bertel O; Maloigne M; Turina M
    J Thorac Cardiovasc Surg; 2001 Sep; 122(3):630-2. PubMed ID: 11547328
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial).
    Januzzi JL; Cannon CP; DiBattiste PM; Murphy S; Weintraub W; Braunwald E;
    Am J Cardiol; 2002 Dec; 90(11):1246-9. PubMed ID: 12450608
    [No Abstract]   [Full Text] [Related]  

  • 56. Defining standards of care for facilitated and direct percutaneous coronary intervention.
    Montalescot G
    Clin Cardiol; 2002 Nov; 25(11 Suppl 1):I27-32. PubMed ID: 12428817
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tirofiban.
    Théroux P
    Drugs Today (Barc); 1999 Jan; 35(1):59-73. PubMed ID: 12973410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of intravenous thrombolysis with half-dose recombinant human prourokinase reduces the rate of tirofiban use during early routine catheterization period.
    Jiang C; Gao J; Luo DL; Guo JT
    Asian J Surg; 2022 Jul; 45(7):1414-1415. PubMed ID: 35440391
    [No Abstract]   [Full Text] [Related]  

  • 59. Tirofiban--an overview of the phase III trials.
    Herrmann HC
    J Invasive Cardiol; 1999 Dec; 11 Suppl C():7C-13C. PubMed ID: 10745615
    [No Abstract]   [Full Text] [Related]  

  • 60. [Erratum to: Platelet inhibition in patients with coronary, cerebral and peripheral macroangiopathy. What, when and how long?].
    Halbach M; Baldus S
    Internist (Berl); 2018 Aug; 59(8):867. PubMed ID: 29931439
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.